A 2025 study revealed that a Chinese herbal compound, CPG, inhibit pulmonary arterial hypertension (PAH) progression by modulating the Mfn2-IP3R3 signaling axis, which regulates ER stress, mitochondrial Ca2+ homeostasis, and autophagy (128). The gene discussed is MFN2; the disease is pulmonary arterial hypertension.